Janone (ALTS) Competitors $5.15 +0.91 (+21.46%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$5.22 +0.06 (+1.26%) As of 04/17/2025 05:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock ALTS vs. ORKA, CYRX, RNAC, TKNO, TSVT, TSHA, ATYR, CMPS, AQST, and ATAIShould you be buying Janone stock or one of its competitors? The main competitors of Janone include Oruka Therapeutics (ORKA), Cryoport (CYRX), Cartesian Therapeutics (RNAC), Alpha Teknova (TKNO), 2seventy bio (TSVT), Taysha Gene Therapies (TSHA), Atyr PHARMA (ATYR), COMPASS Pathways (CMPS), Aquestive Therapeutics (AQST), and Atai Life Sciences (ATAI). These companies are all part of the "pharmaceutical products" industry. Janone vs. Oruka Therapeutics Cryoport Cartesian Therapeutics Alpha Teknova 2seventy bio Taysha Gene Therapies Atyr PHARMA COMPASS Pathways Aquestive Therapeutics Atai Life Sciences Janone (NASDAQ:ALTS) and Oruka Therapeutics (NASDAQ:ORKA) are both small-cap finance companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, community ranking, profitability and dividends. Does the MarketBeat Community favor ALTS or ORKA? Oruka Therapeutics received 17 more outperform votes than Janone when rated by MarketBeat users. CompanyUnderperformOutperformJanoneN/AN/AOruka TherapeuticsOutperform Votes17100.00% Underperform VotesNo Votes Do analysts rate ALTS or ORKA? Oruka Therapeutics has a consensus target price of $39.86, indicating a potential upside of 332.52%. Given Oruka Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Oruka Therapeutics is more favorable than Janone.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Janone 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Oruka Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22 Which has more volatility and risk, ALTS or ORKA? Janone has a beta of 2.08, meaning that its share price is 108% more volatile than the S&P 500. Comparatively, Oruka Therapeutics has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500. Do institutionals & insiders have more ownership in ALTS or ORKA? 6.3% of Janone shares are owned by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are owned by institutional investors. 4.9% of Janone shares are owned by company insiders. Comparatively, 22.7% of Oruka Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has better earnings & valuation, ALTS or ORKA? Oruka Therapeutics has lower revenue, but higher earnings than Janone. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJanone$12.53M6.61-$7.81MN/AN/AOruka TherapeuticsN/AN/A-$5.34M-$5.79-1.59 Is ALTS or ORKA more profitable? Oruka Therapeutics' return on equity of -24.96% beat Janone's return on equity.Company Net Margins Return on Equity Return on Assets JanoneN/A -2,940.01% -39.81% Oruka Therapeutics N/A -24.96%-21.22% Does the media favor ALTS or ORKA? In the previous week, Oruka Therapeutics had 4 more articles in the media than Janone. MarketBeat recorded 5 mentions for Oruka Therapeutics and 1 mentions for Janone. Oruka Therapeutics' average media sentiment score of 0.99 beat Janone's score of -0.50 indicating that Oruka Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Janone Negative Oruka Therapeutics Positive SummaryOruka Therapeutics beats Janone on 12 of the 14 factors compared between the two stocks. Get Janone News Delivered to You Automatically Sign up to receive the latest news and ratings for ALTS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALTS vs. The Competition Export to ExcelMetricJanonePharmaceutical IndustryFinance SectorNASDAQ ExchangeMarket Cap$82.81M$6.45B$10.83B$7.35BDividend YieldN/A3.23%5.98%4.30%P/E RatioN/A6.8921.6717.80Price / Sales6.61231.0325.4397.74Price / CashN/A65.6717.6134.64Price / Book-7.695.932.563.98Net Income-$7.81M$142.99M$1.03B$247.73M7 Day Performance33.77%4.42%1.86%1.81%1 Month Performance22.91%-12.73%-3.72%-6.98%1 Year PerformanceN/A-9.48%535.22%1.37% Janone Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALTSJanoneN/A$5.15+21.5%N/AN/A$82.81M$12.53M0.00170Short Interest ↑High Trading VolumeORKAOruka Therapeutics3.0823 of 5 stars$7.37-3.3%$39.86+441.2%N/A$276.13MN/A-1.18N/AUpcoming EarningsNews CoverageCYRXCryoport2.717 of 5 stars$5.40-1.7%$11.83+119.2%-66.9%$270.76M$228.39M-1.611,020Analyst ForecastAnalyst RevisionNews CoverageRNACCartesian Therapeutics1.7212 of 5 stars$10.42+3.0%$42.14+304.6%-43.2%$269.82M$38.91M-0.2064TKNOAlpha Teknova1.1821 of 5 stars$4.92+9.1%$8.50+72.7%+173.0%$263.39M$37.75M-6.66240Positive NewsGap DownHigh Trading VolumeTSVT2seventy bio1.9569 of 5 stars$4.96+0.1%$5.60+13.0%-1.6%$259.34M$37.86M-2.66440Short Interest ↓Positive NewsTSHATaysha Gene Therapies2.8185 of 5 stars$1.26+1.2%$6.63+427.9%-49.4%$257.28M$8.33M1.99180ATYRAtyr PHARMA2.5894 of 5 stars$2.87+0.5%$18.60+549.2%N/A$257.25M$235,000.00-3.0853Positive NewsCMPSCOMPASS Pathways2.5371 of 5 stars$2.76+2.2%$20.20+632.1%-63.3%$257.17MN/A-1.26120News CoverageAQSTAquestive Therapeutics1.8301 of 5 stars$2.59-1.3%$10.57+309.0%-36.0%$256.57M$57.56M-5.77160Gap DownATAIAtai Life Sciences1.9018 of 5 stars$1.29+1.2%$10.50+717.1%-25.8%$254.82M$308,000.00-1.5980 Related Companies and Tools Related Companies ORKA Alternatives CYRX Alternatives RNAC Alternatives TKNO Alternatives TSVT Alternatives TSHA Alternatives ATYR Alternatives CMPS Alternatives AQST Alternatives ATAI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALTS) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | Sponsored100-year-old investment secret predicts what?!A 100-year-old indicator has quietly predicted nearly every major market meltdown — including the Dot-Com Bust...Weiss Ratings | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Janone Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Janone With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALTS Stock Free ALTS Stock Alerts